Abstracts tagged "Lupus nephritis"

Abstract Number: 690 • 2019 ACR/ARP Annual Meeting
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Ranjan Gupta¹, Dipendra Kumar Mitra ¹ and Sonam Rani ¹, ¹All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Monocytes/macrophages are the most abundant cells infiltrating the glomeruli and in the active urinary sediment of patients with Lupus Nephritis (LN).1 These cells also…
Abstract Number: 1915 • 2019 ACR/ARP Annual Meeting
Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Gregg Silverman¹, Doua Azzouz ¹, Caroline Grönwall ², Iva Gunnarsson ³ and Elisabet Svenungsson ⁴, ¹NYU School of Medicine, New York, NY, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Karolinska Institute, Stockholm, Stockholms Lan, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is the archetypic systemic autoimmune disease, for which there is mounting evidence for roles for intestinal bacteria in the development…
Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, H. Michael Belmont ⁴, Peter Izmirly ⁵, Chandra Mohan ⁶, Ting Zhang ⁷, The Accelerating Medicines Partnership ⁸ and Michelle Petri ⁹, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴New York University School of Medicine, Ney York, ⁵New York University School of Medicine, New York, ⁶University of Houston, Houston, ⁷Biomedical Engineering, University of Houston, Houston, TX, ⁸Multiple Organizations, USA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 2636 • 2018 ACR/ARHP Annual Meeting
Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
Osman Bhatty¹, Sarah Aurit², Rouhin Sen³, Joseph Nahas⁴ and Sunil Jagadesh⁵, ¹Department of Medicine, CHI Creighton University Medical Center, New Hempstead, NY, ²Department of Surgery, CHI Creighton University Medical Center, Omaha, NE, ³Internal Medicine, CHI Creighton University Medical Center, Omaha, NE, ⁴Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE, ⁵Department of Nephrology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Twenty to sixty percent of patients with systemic lupus erythematous (SLE) can progress to lupus nephritis (LN) and those that do can develop end…
Abstract Number: 2662 • 2018 ACR/ARHP Annual Meeting
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
L. Michelle Gomez Mendez¹, Marco Prunotto², Jian Dai³, Paul Brakeman¹, Maria Dall'Era¹, Jay Garg³ and Matthew Cascino³, ¹UCSF, San Francisco, CA, ²Hoffmann-La Roche, Basel, Switzerland, ³Genentech, Inc., South San Francisco, CA
Background/Purpose: Hypertension predicts poor long-term renal outcomes for patients with lupus nephritis (LN) [1, 2]. We sought to characterize relationships between blood pressure and proteinuria…
Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
Carlene Harrison, AstraZeneca, Gaithersburg, MD
Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…
Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…
Abstract Number: 94 • 2018 ACR/ARHP Annual Meeting
Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients
Maria Perez-Ferro¹, Fredeswinda I. Romero-Bueno¹, Cristina Serrano del Castillo², Raquel Largo³, Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Immunology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The MHC class I-related chain A (MICA) is a major ligand for the NKG2D receptor of NK and CD8 T cells. MICA expression at…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 95 • 2018 ACR/ARHP Annual Meeting
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis
Takashi Igawa¹, Kunihiro Ichinose¹, Masataka Umeda¹, Tomohiro Koga¹, Mizuna Eguchi², Momoko Okamoto², Yushiro Endo², Sousuke Tsuji², Ayuko Takatani¹, Toshimasa Shimizu¹, Shoichi Fukui¹, Remi Sumiyoshi², Shinya Kawashiri², Naoki Iwamoto¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³, George C Tsokos⁴ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus(SLE) is multisystem disorder that is caused by tissue damage resulting from antibody and complement-fixing immune complex deposition. Lupus nephritis(LN) is frequent…
Abstract Number: 2958 • 2018 ACR/ARHP Annual Meeting
Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Ishita Aggarwal¹, Laura Trupin², Jing Li³, Lisa Gaynon⁴, Nancy Liu⁵, Chris Schlechter⁶, Louise Murphy⁷, Maria Dall'Era⁶ and Jinoos Yazdany⁶, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, UC San Francisco, San Francisco, CA, ⁴Internal Medicine, California Pacific Medical Center, San Francisco, CA, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, San Francisco, CA, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Lupus nephritis (LN), seen in up to 60% of individuals with SLE, progresses to end stage renal failure in 10-30% of patients within 15…
Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 464 • 2018 ACR/ARHP Annual Meeting
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Grace Chiang^1,2, Sik Nin Wong³, Clara Law⁴, Kwok Piu Lee⁵, Cheuk Chun Szeto⁶, Chi Chiu Mok⁷, Lai-Shan Tam⁸ and Ting Fan Leung⁹, ¹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Paediatrics and Adolescent Medicine, Tune Mun Hospital, Hong Kong, Hong Kong, ⁴Medicine and Therapeutics, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Medicine and Geriatrics, Tune Mun Hospital, Hong Kong, Hong Kong, Hong Kong, ⁸Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Renal disease occurs in 50-70% of all childhood onset systemic lupus erythematosus (cSLE). The prevalence of LN is higher in children and the manifestations…
Abstract Number: 735 • 2018 ACR/ARHP Annual Meeting
Serum Albumin at One Year Predicts Long-Term Renal Outcome
Vinicius Domingues¹, Daniel Goldman², Laurence S Magder³ and Michelle Petri², ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains a major cause of morbidity/mortality in SLE. Our cohort has shown that 20% of SLE patients with lupus nephritis onset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].